A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
← catalyst calendarNCT06103734 · readout in 348 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Withdrawn
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Strategic decision to cancel the study based on adjusted clinical development plan.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-15 | estimated | When the study began enrolling |
| Primary completion | 2027-08-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-02 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Interventions
- Combination product: Zavegepant 10 mg
- Combination product: Placebo - Control 1
- Combination product: Placebo - Control 2
Primary outcomes
what the primary-completion date above is the date OFComparing efficacy of zavegepant with placebo in the acute treatment of migraine as measured by pain freedom at 2-hours post dose during the Double-Blind Treatment (DBT) Phase.
measured 2 hours post-dose
Consistency of efficacy of zavegepant across multiple attacks in the acute treatment of migraine as measured by pain freedom at 2-hours post dose during the DBT Phase.
measured 2 hours post-dose
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed